China CMDE Releases 2026 Revision Guideline for Aesthetic HA Fillers

On February 6, 2026, the Center for Medical Device Evaluation (CMDE) of the National Medical Products Administration (NMPA) issued “Announcement on Releasing the Registration Review Guideline for Aesthetic Sodium Hyaluronate Injectable Fillers (2026 Revision) (Announcement No. 5 of 2026).” The attached “Registration Review Guideline for Aesthetic Sodium Hyaluronate Injectable Fillers (2026 Revision)” took effect immediately upon publication.

The revised guideline applies to aesthetic sodium hyaluronate (HA) injectable fillers intended for dermal or subcutaneous injection to increase tissue volume. Covered uses include correction of nasolabial folds and other wrinkles, as well as augmentation of defined anatomical sites.

A key principle runs through the document: if an applicant considers any listed requirement “not applicable,” the exclusion must be supported by detailed scientific justification.

A Structural Shift: Default Study Coverage with Mandatory Justification

The headline structural change is the introduction of a default study matrix that makes reviewer expectations more explicit.

As an annex to the guideline, “Table 1: Recommended Performance Study Items” lists more than 30 performance-related studies and specifies for each whether it:

• Must be incorporated into the product technical requirements
• Must be submitted as study documentation
• Must be included in shelf-life validation

The practical implication is straightforward: listed studies are presumed applicable unless the applicant can justify exclusion with product-specific scientific rationale. This reduces ambiguity in dossier planning, while also narrowing flexibility for applicants who previously relied on tailored or literature-heavy evidence packages.

From Dossier Completeness to Product-Specific Scientific Substantiation

While the matrix changes how study expectations are organized, the more significant shift is what CMDE appears to expect as proof. Product characteristics — including crosslinking degree, durability, dosing parameters, or lidocaine-related effects — must be supported by direct evidence generated for the specific product under review.

In effect, registration is reframed around demonstrable scientific control, not descriptive documentation. Each claim must be traceable to controlled testing that demonstrates how the specific formulation performs under defined conditions.

Key Technical Changes

Against that backdrop, the technical revisions below show where CMDE has tightened requirements across raw materials, performance validation, biological risk, and lifecycle control.

Pre-Crosslink Raw Material Characterization

Prior Practice2026 Revision RequirementDescription of the crosslinking process was generally sufficient.  
 
Pre-crosslink molecular weight and molecular weight distribution data were not always required. Mandatory submission of study documentation for:  
• Molecular weight  
• Molecular weight distribution  
 
Establishes traceability between raw material properties and final gel performance. 

Crosslinking Uniformity

Prior Practice2026 Revision RequirementAverage indicators such as swelling degree were accepted to characterize crosslinking.  
Uniformity was not independently verified. Documented verification data required for crosslinking uniformity.  
 
Elevated to a controlled performance parameter supported by study data. 

In Vivo Degradation and Metabolism

The revised framework strengthens the link between product degradation behavior and intended treatment regimen.

Prior Practice2026 Revision RequirementDegradation data were recommended and literature citations were often accepted. Product-specific in vivo studies required covering:  • Cross-linking molecule • Degradation products  
 
For multi-course use: must demonstrate complete metabolism within the defined interval.  
 
Literature insufficient without proven technical equivalence. 

Dose and Injection Frequency

The guideline also aligns dosing claims directly with validated safety and effectiveness data.

Prior Practice2026 Revision RequirementDefining a dose range in the IFU was often sufficient.  
 
Limited structured justification required. Must justify with animal or clinical data:  
• Maximum single-site dose  
• Maximum total dose per patient per session  
• Reinjection interval  
 
Labeling must strictly align with validated evidence. 

Drug–Device Combination Products (e.g., Lidocaine)

For device-led combination products, the revision introduces more explicit evidentiary modules.

Prior Practice2026 Revision RequirementBroad references to drug-related data.  
No structured module expectations. Must provide:  
• Drug qualitative and quantitative studies  
• In vitro release studies  
• Drug–gel interaction evaluation  
 
Drug content must be incorporated into product technical requirements. 

Biological Evaluation Scope

Biological evaluation expectations have also expanded.

Prior Practice2026 Revision RequirementFocused primarily on conventional biocompatibility testing. Must assess:  
• Particle-related biological risks (if applicable)  
• Simulate clinical maximum dosage 
 
Expanded biological risk framing. 

Delivery System Compliance (Syringes and Needles)

Regulatory scrutiny now extends more explicitly to externally sourced delivery components.

Prior Practice2026 Revision RequirementAcceptance if component held a registration certificate.  
Overseas supplier data often relied upon. If no China medical device registration certificate or pharmaceutical packaging material filing proof:  
• Submit full physicochemical validation  
• Submit biocompatibility data  
 
Overseas supplier documentation alone insufficient. 

Instructions for Use (IFU) Requirements

Labeling is now closely bound to clinical validation and dosing evidence.

Prior Practice2026 Revision RequirementGeneral prohibition on exaggerated claims.  
Less prescriptive structure. Must include mandatory clauses:  
• Restricted to qualified institutions and trained physicians  
• Exact match to clinically validated indications and injection sites  
• Explicit prohibition of off-label use  
• Detailed course structure, intervals, and maximum doses  
 
If single-course only: must state multi-course safety unverified.  
 
Comprehensive adverse event disclosure required. 

Animal Testing for Efficacy

The role of animal data has been clarified.

Prior Practice2026 Revision RequirementAnimal data sometimes used to support efficacy claims. Efficacy endpoints (e.g., Nasolabial folds) must be supported by human clinical data.  
 
Animal studies limited to degradation validation and biocompatibility endpoints. 

Shelf-Life Validation

Finally, lifecycle performance validation has been reinforced.

Prior Practice2026 Revision RequirementConventional aging studies typically sufficient. Must provide time-point stability data demonstrating:  
• Crosslinking degree stability  
• Extrusion force stability  
 
Functional performance must remain stable across the claimed shelf life 

Strategic Response for Overseas Companies

For international manufacturers operating in China’s aesthetic device market, the overall message is consistent: CMDE is evaluating the product as an integrated system rather than as a set of separate documents. The most effective response is to align technical planning, study strategy, and labeling positioning before dossier compilation begins.

Priority actions include:

Start a Technical Data Gap Analysis

Compare your existing registration files against the “Recommended Performance Research Items” checklist (Attachment 1). Focus on checking:

• Whether molecular weight data before cross-linking is available
• Whether in vivo degradation studies are conducted and cover multi-course scenarios
• Whether the maximum single-use dosage has been validated

Restructure the Drug-Device Combination Product Development Logic

Products containing lidocaine will require an additional 6-8 months of development. At the product finalization stage, drug release methods and validation must be incorporated and aligned with Chinese pharmacopeia standards.

Bind Instruction Manual with Clinical Endpoints

The scope description in the instruction manual must align strictly with the inclusion criteria of the clinical trial. For example, if the clinical trial includes only severe nasolabial fold wrinkle patients, the manual cannot expand to “facial wrinkles” or “overall facial rejuvenation.”

Pre-Compliance Review for Supply Chain

For injected needles or syringes purchased from external suppliers, if they do not have a Chinese medical device registration certificate, alternate suppliers should be sought, or additional validation studies must be initiated.

Addressing these issues during development — rather than during review — reduces the likelihood of rework or supplemental testing.

Final Perspective

The 2026 revision establishes a clearer, but more demanding, pathway for aesthetic HA fillers in China. It replaces flexible dossier packaging with structured expectations for product-specific scientific control across raw materials, performance, dosing, biological risk, labeling, delivery systems, and stability.

Manufacturers that approach compliance as a lifecycle-integrated process — and build a coherent evidence chain from development through registration — will be better positioned to maintain and expand access to China’s aesthetic device market.

Against this backdrop, aligning technical strategy, study design, and registration documentation with the revised requirements is critical to delivering consistent, product-specific submissions. For support in navigating this transition, contact Cisema today.

Further Information

• Explore Cisema’s services for Medical Device registration in China.

References

• “Announcement on Releasing the Registration Review Guideline for Aesthetic Sodium Hyaluronate Injectable Fillers (2026 Revision) (Announcement No. 5 of 2026)” — Center for Medical Device Evaluation, NMPA
• “Technical Review Guideline for Registration of Sodium Hyaluronate Facial Injectable Filling Materials (Announcement No. 7 of 2016)” — Center for Medical Device Evaluation, NMPA